Colliers Securities analyst Kyle Bauser maintained a Hold rating on Chembio Diagnostics (CEMI – Research Report) today. The company's shares closed last Tuesday at $1.56, close to its 52-week low of $1.56. According to TipRanks.com, Bauser is a 3-star analyst with an average return of 4.1% and a 44.7% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Semler Scientific, Motus Gi Holdings, and Lantern Pharma. The the analyst consensus on Chembio Diagnostics is currently a Hold rating. See the top stocks recommended by analysts >> Based on Chembio Diagnostics' latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $9.
https://www.tipranks.com/news/blurbs/chembio-diagnostics-cemi-receives-a-hold-from-colliers-securities?utm_source=advfn.com&utm_medium=referral
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Chembio Diagnostics Charts.
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Chembio Diagnostics Charts.